Major results of a phase III comparative multicenter study on the follitropin alfa biosimilar (Primapur®) and the original follitropin alfa (Gonal-f®)

• Asıl Yazarlar: Z. B. Barakhoeva (Yazar), L. A. Vovk (Yazar), I. V. Zorina (Yazar), N. Yu. Belousova (Yazar), T. A. Teterina (Yazar), S. A. Yakovenko (Yazar), V. P. Apryshko (Yazar), Yu. A. Fetisova (Yazar), N. A. Marilova (Yazar), E. G. Morozova (Yazar), M. M. Ovchinnikova (Yazar), M. A. Tishenko (Yazar), Yu. V. Sherbatyuk (Yazar), A. V. Kolotovkina (Yazar), A. A. Miskun (Yazar), G. V. Kasyanova (Yazar), L. G. Sichinava (Yazar), R. I. Shalinа (Yazar), M. A. Polzikov (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: IRBIS LLC, 2018-11-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

A clinical study on the efficacy and safety of follitropin alfa has been conducted. The aim of the study was to confirm the therapeutic equivalence between the follitropin alfa biosimilar (Primapur®) and the reference medication (Gonal-f®) in controlled induction of superovulation within the assiste...